Tenofovir

Generic Name: Tenofovir

Brand Names: Vemlidy, Tenofovir disoproxil Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₄N_₅O_₄P

CAS Number: 147127-20-6

Unique Ingredient Identifier: W4HFE001U5

Background: Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of tenofovir disoproxil and tenofovir alafenamide in order to obtain oral bioavailability.

Indication: Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.

To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.

Clinical Trials

Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B

Not yet recruiting

Conditions: Tenofovir Disoproxil Fumarate
Renal Function Disorder
Chronic HBV Infection

First Posted Date: 2025-03-26

Last Posted Date: 2025-04-04

Lead Sponsor: Assiut University

Target Recruit Count: 172

Registration Number: NCT06896630

Locations: 🇪🇬
Faculty of Medicine, Assuit, Egypt

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Phase 4

Active, not recruiting

Conditions: Hepatitis B, Chronic

Interventions: Drug: Tenofovir Amibufenamide（TMF）

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-19

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 640

Registration Number: NCT06743438

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Not Applicable

Conditions: Chronic Hepatitis B

Interventions: Drug: Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate

First Posted Date: 2024-11-27

Last Posted Date: 2024-12-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT06707922

To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients

Phase 2

Not yet recruiting

Conditions: Hepatitis B Virus
Liver Transplant
Renal Insufficiency

Interventions: Drug: Tenofovir Alafenamide Citrate

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-04

Lead Sponsor: Jongman Kim

Target Recruit Count: 108

Registration Number: NCT06589518

Bioequivalence Study of Two Products of Tenofovir Alafenamide 25 mg Film Tablet in Healthy, Adult, Human Subjects

Phase 1

Completed

Conditions: Chronic Hepatitis B in Adults and Paediatric Patients

Interventions: Drug: Tenofovir Alafenamide Film coated Tablet
Drug: Vemlidy® film-coated tablets

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-18

Lead Sponsor: Humanis Saglık Anonim Sirketi

Target Recruit Count: 42

Registration Number: NCT06592300

Locations: 🇮🇳
Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India

Antiviral Clinical Trial for Long Covid-19

Phase 2

Recruiting

Conditions: Long Covid

Interventions: Drug: Placebo
Drug: tenofovir disoproxil/emtricitabine
Drug: Selzentry

First Posted Date: 2024-07-19

Last Posted Date: 2024-12-20

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 90

Registration Number: NCT06511063

Locations: 🇺🇸
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York, United States

From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

Phase 1

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: Terbinafine
Drug: Placebo
Drug: Tenofovir

First Posted Date: 2024-03-06

Last Posted Date: 2025-02-07

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 36

Registration Number: NCT06295328

Locations: 🇳🇱
Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

Phase 3

Not yet recruiting

Conditions: Prevention

Interventions: Drug: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
Drug: Cabotegravir Tablets, for oral use.
Procedure: Rectal Biopsies
Drug: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.

First Posted Date: 2024-02-23

Last Posted Date: 2024-02-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 322

Registration Number: NCT06273943

Locations: 🇫🇷
Hôpital Lariboisière, Paris, Ile De France, France
🇫🇷
Hôpital Saint Louis, Paris, Ile De France, France
🇫🇷
Hôpital Hôtel Dieu, Paris, Ile De France, France

and more 5 locations